OS Therapies (OSTX)
OS Therapies Statistics
Share Statistics
OS Therapies has 28.1M shares outstanding. The number of shares has increased by null% in one year.
| 28.1M |
| n/a |
| n/a |
| n/a |
| n/a |
| 919 |
| 0.4% |
Short Selling Information
The latest short interest is 259.44K, so 0.92% of the outstanding shares have been sold short.
| 259.44K |
| 0.92% |
| 1.18% |
| 1 |
Valuation Ratios
The PE ratio is -0.01 and the forward PE ratio is -14.91. OS Therapies's PEG ratio is 0.
| -0.01 |
| -14.91 |
| 0 |
| 0.6 |
| 0.01 |
| -12.27 |
| 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for OS Therapies.
| n/a |
| n/a |
| n/a |
| n/a |
Financial Position
The company has a current ratio of 1.2, with a Debt / Equity ratio of 0.
| 1.2 |
| 1.2 |
| 0 |
| n/a |
| n/a |
| 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| n/a |
| n/a |
| n/a |
| n/a |
| $-2,220,734,500 |
| 4 |
| 0 |
| n/a |
Taxes
| n/a |
| 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is -5.55, so OS Therapies's price volatility has been lower than the market average.
| -5.55 |
| n/a |
| 1.63 |
| 2.57 |
| 48.61 |
| 232,363 |
Balance Sheet
The company has 5.53M in cash and 0 in debt, giving a net cash position of 5.53M.
| 5.53M |
| n/a |
| n/a |
| -40.4B |
| 4.25B |
| 559.09M |
Cash Flow
In the last 12 months, operating cash flow was -7.28M and capital expenditures 0, giving a free cash flow of -7.28M.
| -7.28M |
| n/a |
| -7.28M |
| -0.35 |
Margins
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
Dividends & Yields
OSTX does not appear to pay any dividends at this time.
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
| n/a |
Analyst Forecast
The average price target for OSTX is $19.5, which is 1134.2% higher than the current price. The consensus rating is "Buy".
| $19.5 |
| 1134.2% |
| Buy |
| 4 |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| n/a |
| n/a |
| n/a |
| n/a |
Scores
| -17.41 |
| 2 |